Chembio Diagnostics, Inc., together with its subsidiaries, develops, manufactures, and commercializes point-of-care (POC) diagnostic tests that are used to detect or monitor diseases. It offers tests for HIV and Syphilis, and Zika virus. The company also develops tests for malaria, Dengue virus, chikungunya virus, Ebola, Lassa, Marburg, leptospirosis, Rickettsia typhi, Burkholderia pseudomallei, and Orientia tsutsugamushi. It sells its products under the STAT-PAK, SURE CHECK, STAT VIEW, or DPP trademarks, as well as under the private labels of its marketing partners to medical laboratories and hospitals, governmental and public health entities, non-governmental organizations, medical professionals, and retail establishments in the United States and internationally. The company has collaboration agreements with Concussion Science Group Division of Perseus Science Group LLC for the development of a POC diagnostic test for traumatic brain injury; international diagnostics company to develop a POC diagnostic test for a specific type of cancer; and AstraZeneca for the development of a POC assay for a novel biomarker, as well as with LumiraDx to develop POC diagnostic tests. Chembio Diagnostics, Inc. was founded in 1985 and is headquartered in Medford, New York.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone631-924-1135
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$33.41 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date5/8/2019 (Estimated)
OptionableNot Optionable
Chembio Diagnostics (NASDAQ:CEMI) Frequently Asked Questions
What is Chembio Diagnostics' stock symbol?
Chembio Diagnostics trades on the NASDAQ under the ticker symbol "CEMI."
How were Chembio Diagnostics' earnings last quarter?
Chembio Diagnostics Inc (NASDAQ:CEMI) announced its earnings results on Thursday, March, 7th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.04. The firm had revenue of $7.60 million for the quarter, compared to analyst estimates of $6.74 million. Chembio Diagnostics had a negative return on equity of 31.85% and a negative net margin of 23.54%. View Chembio Diagnostics' Earnings History.
When is Chembio Diagnostics' next earnings date?
What guidance has Chembio Diagnostics issued on next quarter's earnings?
Chembio Diagnostics issued an update on its FY 2019 earnings guidance on Thursday, March, 7th. The company provided EPS guidance of for the period. The company issued revenue guidance of $36-40 million, compared to the consensus revenue estimate of $40.39 million.
What price target have analysts set for CEMI?
3 equities research analysts have issued 12-month price targets for Chembio Diagnostics' shares. Their forecasts range from $9.00 to $14.00. On average, they expect Chembio Diagnostics' stock price to reach $11.50 in the next twelve months. This suggests a possible upside of 116.2% from the stock's current price. View Analyst Price Targets for Chembio Diagnostics.
What is the consensus analysts' recommendation for Chembio Diagnostics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Chembio Diagnostics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Chembio Diagnostics.
Has Chembio Diagnostics been receiving favorable news coverage?
News headlines about CEMI stock have been trending somewhat negative on Tuesday, InfoTrie Sentiment Analysis reports. The research firm identifies positive and negative news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Chembio Diagnostics earned a news sentiment score of -1.8 on InfoTrie's scale. They also gave news stories about the company a news buzz of 4.0 out of 10, meaning that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.
Who are some of Chembio Diagnostics' key competitors?
Some companies that are related to Chembio Diagnostics include ImmunoGen (IMGN), Sinovac Biotech (SVA), Progenics Pharmaceuticals (PGNX), BioDelivery Sciences International (BDSI), Abeona Therapeutics (ABEO), Kadmon (KDMN), Albireo Pharma (ALBO), Keryx Biopharmaceuticals (KERX), Insys Therapeutics (INSY), Urovant Sciences (UROV), Concert Pharmaceuticals (CNCE), MediciNova (MNOV), Osmotica Pharmaceuticals (OSMT), Karyopharm Therapeutics (KPTI) and Kindred Biosciences (KIN).
What other stocks do shareholders of Chembio Diagnostics own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Chembio Diagnostics investors own include Prospect Capital (PSEC), Calumet Specialty Products Partners, L.P (CLMT), Two Harbors Investment (TWO), Alkaline Water (WTER), Blackrock Capital Investment (BKCC), Viper Energy Partners (VNOM), Summit Midstream Partners (SMLP), Washington Prime Group (WPG), Novocure (NVCR) and Roper Technologies (ROP).
Who are Chembio Diagnostics' key executives?
Chembio Diagnostics' management team includes the folowing people:
- Mr. John J. Sperzel III, Pres, CEO & Director (Age 55)
- Mr. Neil A. Goldman, Exec. VP & CFO (Age 51)
- Mr. Javan Esfandiari, Chief Science & Technology Officer and Exec. VP (Age 52)
- Dr. Robert Passas Ph.D., Sr. VP & Chief Commercial Officer (Age 65)
- Mr. David A. Gyorke, Sr. VP & COO (Age 59)
Who are Chembio Diagnostics' major shareholders?
Chembio Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include Nantahala Capital Management LLC (4.77%), ARS Investment Partners LLC (3.80%), Royce & Associates LP (2.73%), Segall Bryant & Hamill LLC (2.03%), Ingalls & Snyder LLC (1.85%) and Gagnon Securities LLC (1.78%). Company insiders that own Chembio Diagnostics stock include John Gary Potthoff, Neil A Goldman, Norman H Pessin and Robert Passas. View Institutional Ownership Trends for Chembio Diagnostics.
Which institutional investors are selling Chembio Diagnostics stock?
Which institutional investors are buying Chembio Diagnostics stock?
CEMI stock was purchased by a variety of institutional investors in the last quarter, including Nantahala Capital Management LLC, Segall Bryant & Hamill LLC, Royce & Associates LP, Stonepine Capital Management LLC, Wexford Capital LP, Gagnon Advisors LLC, Gagnon Securities LLC and Geode Capital Management LLC. Company insiders that have bought Chembio Diagnostics stock in the last two years include John Gary Potthoff, Neil A Goldman, Norman H Pessin and Robert Passas. View Insider Buying and Selling for Chembio Diagnostics.
How do I buy shares of Chembio Diagnostics?
Shares of CEMI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Chembio Diagnostics' stock price today?
One share of CEMI stock can currently be purchased for approximately $5.32.
How big of a company is Chembio Diagnostics?
Chembio Diagnostics has a market capitalization of $91.32 million and generates $33.41 million in revenue each year. The company earns $-7,870,000.00 in net income (profit) each year or ($0.55) on an earnings per share basis.
What is Chembio Diagnostics' official website?
How can I contact Chembio Diagnostics?
Chembio Diagnostics' mailing address is 3661 HORSEBLOCK ROAD, MEDFORD NY, 11763. The company can be reached via phone at 631-924-1135 or via email at [email protected]
MarketBeat Community Rating for Chembio Diagnostics (NASDAQ CEMI)
MarketBeat's community ratings are surveys of what our community members think about Chembio Diagnostics and other stocks. Vote "Outperform" if you believe CEMI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CEMI will underperform the S&P 500 over the long term. You may vote once every thirty days.
